Chinese ADCs Go Global: From “Following” to “Competing on the Same Stage,” China’s Innovative Drugs Are Reshaping the Global ADC Landscape

In recent years, antibody-drug conjugates (ADCs) have undoubtedly become one of the most closely watched areas in global oncology innovation.

From HER2-positive breast cancer to lung cancer, gastric cancer, urothelial carcinoma, and a growing range of solid tumors, ADCs continue to expand the boundaries of cancer treatment. At the same time, a noteworthy trend is emerging across the global pharmaceutical industry: Chinese ADC companies are entering international markets at an unprecedented pace.

Against the backdrop of increasing integration across the global biopharmaceutical industry, professional medical service platforms, including DengYueMed, continue to monitor the internationalization of Chinese ADCs, providing industry stakeholders and patients with insights into cutting-edge therapies and global pharmaceutical developments.

However, behind the growing wave of Chinese ADCs going global, an important question continues to attract industry attention:

How far have Chinese ADCs progressed? What gaps still exist compared with global pharmaceutical leaders? And what unique advantages do Chinese companies bring to the field?

Why Have ADCs Become One of the Hottest Areas in Oncology?

ADCs are often referred to as “biological missiles.”

Their core concept combines three essential components:

● Monoclonal Antibody

● Linker

● Cytotoxic Payload

These elements work together as a single therapeutic system.

The antibody precisely recognizes tumor cells;

The linker controls drug release;

The payload destroys cancer cells.

In theory, ADCs combine the precision of targeted therapies with the potent anti-tumor effects of chemotherapy, making them one of the most promising approaches in precision oncology.

In recent years, several blockbuster ADCs have achieved significant commercial success, driving rapid growth of the global ADC market.

As a result, ADCs have become one of the most active areas of innovation in oncology drug development.

Why Has the Global Expansion of Chinese ADCs Accelerated?

If we look back five years, the global ADC market was largely dominated by pharmaceutical companies from Europe, the United States, and Japan.

Key players included:

● AstraZeneca

● Daiichi Sankyo

● Pfizer

● Roche

● Gilead Sciences

Chinese companies were largely viewed as technology followers.

However, since 2023, the landscape has changed significantly.

An increasing number of multinational pharmaceutical companies have actively sought partnerships with Chinese ADC developers.

This shift is primarily driven by three factors:

First, Significant Improvements in Domestic ADC Innovation

Early Chinese ADC programs were largely developed using established technology platforms.

In recent years, however, more companies have built proprietary ADC technologies, including:

● Novel linker technologies;

● Next-generation payloads;

● Site-specific conjugation technologies;

● Bispecific ADC platforms;

● Dual-payload ADC platforms.

As a result, innovation capabilities have improved substantially.

Second, Strong Clinical Development Efficiency

Compared with Western markets, China offers access to a large patient population.

With clearly defined targets and well-designed clinical strategies:

● Patient enrollment is often faster;

● Clinical development progresses more efficiently;

● Key data can be generated in a shorter timeframe.

This allows some Chinese ADC programs to obtain critical clinical evidence more rapidly.

Third, Increasing Pipeline Pressures for Multinational Pharma

As major pharmaceutical companies approach patent expirations for key products, many are seeking to strengthen their oncology pipelines.

China has emerged as one of the most important sources of ADC innovation globally.

This has contributed to a growing number of large-scale licensing and partnership transactions in recent years.

The globalization of Chinese ADCs has evolved from isolated cases into a clear industry trend.

Where Do Chinese ADCs Still Lag Behind Multinational Companies?

Despite remarkable progress, there are still areas where Chinese ADC developers trail leading global companies.

Limited Global Clinical Development Experience

Most Chinese ADC programs continue to rely heavily on clinical data generated within China.

In contrast, multinational pharmaceutical companies often possess:

● Extensive global multicenter trial experience;

● Deep regulatory engagement expertise in the U.S. and Europe;

● International patient management capabilities;

● Global medical affairs organizations.

These capabilities require years of accumulation and operational experience.

For a truly global innovative medicine, strong clinical data alone is not sufficient.

Global development expertise is equally important.

Original Innovation Still Needs Further Advancement

Many Chinese ADC programs remain focused on highly competitive targets such as:

● HER2

● TROP2

● Claudin18.2

● HER3

While some products have demonstrated meaningful differentiation, the proportion of First-in-Class innovations still has room for growth.

By comparison, global leaders often invest earlier in novel targets and new biological mechanisms.

Commercialization Infrastructure Requires Further Development

Regulatory approval is only the beginning.

Successful commercialization in international markets also requires:

● Market access capabilities;

● Reimbursement negotiation expertise;

● Commercial promotion infrastructure;

● Global supply chain management.

These remain relative weaknesses for many Chinese biotech companies.

The Strengths of Chinese ADCs Are Gaining Global Recognition

While challenges remain, Chinese ADC developers are also demonstrating increasingly significant competitive advantages.

Speed of Innovation

Chinese ADC companies generally operate with highly efficient decision-making processes.

From target validation to IND submission and clinical development, timelines are often shorter than those of large multinational pharmaceutical companies.

In the highly competitive ADC space, speed itself has become a strategic advantage.

Cost Advantages

ADC development and manufacturing are highly expensive.

China's mature biopharmaceutical ecosystem helps reduce:

● Research and development costs;

● Clinical trial costs;

● Manufacturing costs.

This significantly improves overall development efficiency.

Rapid Progress in Engineering Innovation

Chinese companies have made notable advances in several key ADC technologies, including:

● Site-specific conjugation;

● Cleavable linker technologies;

● Novel topoisomerase inhibitor payloads;

● Bispecific ADC platforms;

● Dual-payload ADC platforms.

Some technology platforms have already reached internationally competitive standards.

Industry discussions are increasingly shifting from “Can we develop ADCs?” to “Who can develop the next generation of ADCs?”

The Next Phase of Competition: From Fast-Follow to Best-in-Class

One of the key reasons behind the success of Chinese ADCs in recent years has been the Fast-Follow strategy.

This approach focuses on developing improved products based on validated targets.

However, future competition is expected to evolve.

The industry is increasingly focused on:

● Better efficacy;

● Lower toxicity;

● More precise patient selection;

● More effective combination treatment strategies.

In other words:

The next stage of competition will no longer be about whether an ADC exists, but about which ADC performs better.

Best-in-Class innovation is expected to become the next major objective for Chinese ADC companies pursuing global expansion.

Notably, as more Chinese ADC programs enter international clinical development, demand for global drug accessibility, cross-border pharmaceutical services, and greater transparency in innovative drug information continues to grow. Platforms such as DengYueMed are helping patients and healthcare professionals stay informed about emerging treatment opportunities by closely tracking global ADC development and international collaboration trends.

What Does the Global Expansion of Chinese ADCs Mean for Patients?

For patients, the internationalization of ADCs represents more than global recognition of Chinese innovation.

More importantly, an increasing number of therapies originating in China are beginning to contribute to the development of global oncology treatment standards.

As more Chinese ADCs enter international multicenter clinical trials and gradually obtain regulatory approvals overseas, patients worldwide will gain access to a broader range of treatment options.

At the same time, Chinese patients may benefit from earlier access to cutting-edge ADC therapies, creating a positive cycle between pharmaceutical innovation and clinical benefit.

Conclusion

From technology acquisition to independent innovation, and from domestic development to global licensing, China’s ADC industry is undergoing a transformation from quantitative growth to qualitative advancement.

Objectively speaking, Chinese companies still face challenges in areas such as global development experience, original innovation, and commercialization capabilities. Nevertheless, the advantages demonstrated by Chinese ADC developers in R&D efficiency, engineering innovation, and industrial ecosystem integration are increasingly being recognized worldwide.

The future competition in the ADC sector is no longer a simple story of China catching up with the rest of the world—it is becoming a contest among global innovators competing on the same stage.

As more Chinese ADCs enter international markets, China’s innovative pharmaceutical industry is evolving from a participant into an important driver of global oncology innovation. For DengYueMed, which continues to follow developments in innovative medicines worldwide, documenting and witnessing this new wave of Chinese ADC globalization will remain an important part of helping patients stay informed about emerging therapeutic advances.